Zoloft (Sertraline): Mechanism, Clinical Applications and Production Strategy

Sura Narendra Kumar[1], Cherishma Kumar Subhasa[2], Monisha Arun[2], Samridhi Makkar[2], Shashank D[2], Vishwam Dixit[2]

ABSTRACT

Zoloft, an antidepressant and anxiolytic, frequently given to people afflicted with depression, has been the focus of in-depth clinical research, receiving a lot of attention for both its efficiency and safety performance. Pharmacology has made significant strides in the last few decades in treating a wide range of mental health issues. The emergence of selective serotonin reuptake inhibitors (SSRIs) has been one such notable breakthrough. A key player in this pharmacological landscape is Sertraline hydrochloride, better known by its brand name Zoloft. This analysis provides a thorough examination of its pharmacological mechanisms, clinical uses, production, future scope and its various uses and effects towards certain mental health disorders.

Keywords: Zoloft, SSRIs, Depression, Obsessive compulsive disorder (OCD), Post-traumatic stress disorder (PTSD), Social anxiety disorder, enantiomeric excess

INTRODUCTION

Depression is the most prevalent psychiatric condition that currently affects almost 5% of the world's population. Depressive disorders are still challenging to treat despite a variety of therapy options [1]. Selective serotonin reuptake inhibitors, or SSRIs, are now a mainstay of treatment for various depressive disorders. The various SSRIs in practice are Paroxetine, Sertraline, Citalopram, Escitalopram, Fluoxetine and Fluvoxamine. In this review, we aim to elucidate the basic mechanism of action of Zoloft, one of the more commonly prescribed antidepressants, explain its clinical applications in treating mental disorders such as obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and social anxiety disorder by comparing its effectiveness against cognitive behavioral therapy as well as against other medication, we also aim to simplify its production strategy. Every selective serotonin reuptake inhibitor (SSRI), Sertraline in this case, possesses distinct pharmacokinetics, pharmacodynamics, adverse effect profiles, and efficacy, making them mostly appropriate for treatments of various psychiatric disorders [1]. Zoloft plays a significant role in pharmaceutical revenue due to its widespread usage in treating depression, anxiety, and OCD. Its economic impact extends to healthcare costs, influencing expenditures on prescriptions and therapy.

MECHANISM OF ACTION

The structure of Sertraline- [(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-*N*-me- thyl-1-naphthalenamine] and its metabolite Desmethylsertraline-[(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4–tetrahydro-1-naphthalenamine] are shown in fig.



Sertraline



Desmethylsertraline

The diagrammatic representation of a synapse as shown in fig. 1, consisting of the presynaptic and postsynaptic neurons. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter made from the amino acid Tryptophan. Under normal circumstances, Serotonin is released by the presynaptic neuron and passes through a channel binding to the serotonin receptors on the postsynaptic neuron. This leads to a chain reaction that is eventually responsible for elevation of mood and an optimistic state of mind. While this occurs only for a brief period of time as serotonin heads back into the presynaptic neuron where it is degraded by an enzyme called Monoamine Oxidase (MOA). A naphthalene amine derivative, Sertraline primarily acts by preventing serotonin from being taken up by the presynaptic neuron [2]. This leads to a rise in the amount of serotonin at the post synapses in the central nervous system (CNS) causing numerous functional alterations responsible for antidepressant action [3]. Sertraline is ingested once daily and has a half-life of 24-26 hours with peak plasma drug concentrations after 4-10 hours [2][4]. Sertraline demethylases hepatically to form desmethyl-sertraline, this reaction is catalyzed by multiple cytochrome P450 (CYP) isoforms, mainly CYP3A4 and CYP2B6 while CYP2C19 and CYP2D6 also contributes to some of the activity [5] [6].



Fig.1 Serotonin reuptake is inhibited by the action of Sertraline so Serotonin remains bound to the serotonin receptors on the postsynaptic neuron and thus aids in antidepressant action

CLINICAL APPLICATIONS

Zoloft is commonly prescribed as a selective serotonin reuptake inhibitor (SSRI) for the treatment of conditions like depression, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder and social anxiety disorder.

Few of the key aspects of clinical trials for Zoloft are:

Post-Traumatic Stress Disorder (PTSD): It is a persistent psychiatric disorder which develops over years, characterized by signs of hyperarousal, avoidance and relieving stressful experiences [7]. Current research on PTSD emphasizes the significance of conducting clinical trials that consider the patient's preference and compare medications such as SSRIs to cognitive-behavioral therapies (CBT), including prolonged exposure. Based on recent randomized controlled trials, prolonged exposure (PE) tends to produce better improvements when compared to SSRIs. In both the pre-treatment and post-treatment outcomes of the study conducted, indicated that patients tend to prefer prolonged exposures over the use of sertraline, even in cases of self-reported PTSD [8]. In another research, conducted over a 24-month period, involved 200 participants who received either PE or sertraline. The findings revealed substantial improvements in fear of intimacy, distress from negative social cognitions, and social aid for trauma survivors with social functioning difficulties. In conclusion, the study supports the positive effects of PTSD treatments like PE and sertraline on social functioning, suggesting improved results for individuals with complicated life challenges[9].

Social Anxiety Disorder (SAD): Characterized by excessive fear and anxiety in social situations, and a persistent dread of being judged by others, and this can have extreme and distressing consequences on one's social life, career, and education [10]. A recent study compared sertraline and psychotherapy, specifically group cognitive-behavioral therapy (GCBT) or group psychodynamic therapy (GPT), in treating social anxiety disorder (SAD). The double-blind, randomized controlled trial involved 146 participants and lasted 20 weeks. Results showed that sertraline showed better improvement in social anxiety symptoms compared to the placebo [11]. Based on the data collected from 20 randomized controlled trials, RCT of five drugs, in the SSRI class, sertraline is regarded as the first line medication for SAD. The dosage and treatment varies from individual to individual and should be given a minimum of 6 to 12 months for proving the drug's efficacy and has been proven that the long-term relapse has been prevented. Sertraline has proved to be more effective against other antidepressants such as Brofaromine, Mirtzapine, Imipramine etc. as well as some antipsychotic drugs like Olanzapine, Ketamine and Oxytocin, etc [12].

Obsessive-Compulsive Disorder (OCD): It is a prominent mental illness in which patients exhibit the characteristic obsession, most of which are frequently linked to anxiety, intrusive thoughts, unwanted impulses, ideas, or designs [13]. One of the earliest antidepressant drugs used to treat OCD was Clomipramine, but due to its acute side effects, an SSRI class of pharmacotherapy drugs was developed, and these have proved to be better and more effective against OCD. The SSRI group includes escitalopram, paroxetine, citalopram, fluvoxamine, fluoxetine and sertraline [14]. In a single-blind trial of sertraline, followed by a 28-week double-blind trial of sertraline or placebo in individuals who had achieved a sustained response during the initial trial. The results indicated that sertraline demonstrated sustained efficacy and was well tolerated during the 80-week study. It showed significantly higher efficacy than placebo in preventing relapse, insufficient clinical response, and acute exacerbation of OCD symptoms. Sertraline was observed to be generally well-tolerated, taking into account the mild to moderate side effects. The double-blind phase of the trial exhibited low relapse rates (<5%). This is in contrast to other research that indicates the greater chances of relapse following the discontinuation of SSRIs [15].

PRODUCTION STRATEGY



Sertraline Synthesis for commercial Production Explore new technologies that can improve the synthesis process of sertraline.This should increase efficiency, enhance purity, reduce environmental impact and be cost- effective compared to existing synthesis routes.Researchers analyze factors such as scalability, reproducibility, safety, regulatory compliance, and compatibility with existing infrastructure. Researchers evaluate the technical, regulatory, financial, and operational risks associated with adopting novel synthesis methods. Focus on development of continuous chromatography, a method used for separating and purifying chemical compounds continuously rather than working with batches. To evaluate the viability and efficiency of continuous chromatography for industrial- scale application, preliminary study and pilot projects are carried out. The synthesis process is improved by getting rid of substances like D-mandelic acid and titanium chloride thus, increasing environmental sustainability, lowering costs, and improving process efficiency. Another strategy used to enhance sertraline production is catalytic reduction of prochiral ketones using continuous chromatography. Investigation of oxazaborolidine as potential catalysts for the reduction of prochiral ketones. This method aims to identify catalysts with high efficiency, selectivity and stability for catalytic reduction reactions. Diphenyl oxazaborolidine is a highly effective catalyst for producing high enantiomeric excess alcohol which helped in the production of sertraline[16]. Integration of Continuous Chromatography and Catalytic Reduction into the Sertraline Synthesis Process. Current synthesis protocols are adjusted to include methods for catalytic reduction and continuous chromatography. Continuous chromatography can transform drug development by simplifying the purification step and ensuring constant purity levels. It maintains purity throughout the commercial development process by ensuring product quality ,decreasing the danger of regulatory setbacks and eliminating the need for repeated studies or purging procedures. This is the commercial route to synthesis sertraline using new technologies in pharmaceutical synthesis. It encapsulates the key progress, benefits, and potential future implications of the research and development efforts.

FUTURE SCOPE

In the attempts to separate the antidepressant effects from the negative effects of SSRIs were developed [17]. They work by blocking the reabsorption (reuptake) of the neurotransmitter serotonin in the brain, leading to increased levels of serotonin in the synaptic clefts between neurons [18]. This increase in serotonin is believed to improve mood and alleviate symptoms of depression, anxiety, PTSD, GAD, etc. SSRIs do not typically exhibit the severe cognitive,

cardiac, and other physical side effects commonly associated with tricyclic antidepressants (TCAs). Additionally, SSRIs are not considered toxic in cases of overdose [19]. SSRIs have been at the forefront of depression treatment for a while now, and it seems like they're here to stay as the preferred option. Recent research even shows that certain SSRIs, like paroxetine, could be effective for patients dealing with depression alongside other health conditions. Additionally, combining SSRIs with other medications might speed up their antidepressant effects. Notably, some SSRIs are already established treatments for anxiety disorders, and there's ongoing exploration into their potential for treating other anxiety-related issues. Despite the emergence of new medications, SSRIs continue to shine as the top choice for depression treatment, thanks to their proven efficacy, manageable side effects and for managing a range of anxiety disorders, solidifying their pivotal role in mental health care [20].

CONCLUSION

Zoloft (sertraline) is a well-established SSRI medication with a proven track record in treating various mental health disorders, including OCD, depression, PTSD, and social anxiety disorder. This review paper comprehensively explored the mechanism of action, clinical applications, production strategies, and future scope of Zoloft.

Key takeaways from this review include:

- Sertraline acts by inhibiting the reuptake of serotonin, leading to increased levels of this neurotransmitter in the CNS.
- Clinical trials support the safety and efficacy of Zoloft in treating various mental health conditions.
- New production technologies, such as continuous chromatography and catalytic reduction, are being explored to improve the efficiency and sustainability of sertraline synthesis.
- SSRIs, including Zoloft, are likely to remain a mainstay in the treatment of depression and anxiety disorders for the foreseeable future, with ongoing research exploring their potential for managing other mental health conditions.

Overall, Zoloft remains a valuable medication in the fight against mental health challenges, and its continued development and exploration hold promise for improving the lives of individuals struggling with these conditions.

REFERENCES

[1]A. N. Edinoff *et al.*, "Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review," *Neurology International*, vol. 13, no. 3, pp. 387–401, Aug. 2021, doi: https://doi.org/10.3390/neurolint13030038.

[2]C. L. DeVane, H. L. Liston, and J. S. Markowitz, "Clinical Pharmacokinetics of Sertraline," *Clinical Pharmacokinetics*, vol. 41, no. 15, pp. 1247–1266, 2002, doi: https://doi.org/10.2165/00003088-200241150-00002.

[3] J. Ritter, R. J. Flower, G. Henderson, Yoon Kong Loke, and H. P. Rang, *Rang and Dale's Pharmacology*, 9th ed. Edinburgh: Elsevier, 2020.

[4]G. MacQueen, L. Born, and M. Steiner, "The Selective Serotonin Reuptake Inhibitor Sertraline: Its Profile and Use in Psychiatric Disorders," *CNS Drug Reviews*, vol. 7, no. 1, pp. 1–24, Jun. 2006, doi: https://doi.org/10.1111/j.1527-3458.2001.tb00188.x.

[5]R. Huddart *et al.*, "PharmGKB summary: sertraline pathway, pharmacokinetics," *Pharmacogenetics and Genomics*, vol. 30, no. 2, pp. 26–33, Feb. 2020, doi: https://doi.org/10.1097/fpc.0000000000000392.

[6]Murdoch, David, and Donna McTavish. "Sertraline." Drugs, vol. 44, no. 4, Oct. 1992, pp. 604–624, https://doi.org/10.2165/00003495-199244040-00007.

[7]B. Kelmendi, T. G. Adams, S. Yarnell, S. Southwick, C. G. Abdallah, and J. H. Krystal, "PTSD: from neurobiology to pharmacological treatments," European Journal of Psychotraumatology, vol. 7, no. 1, p. 31858, Nov. 2016, doi: https://doi.org/10.3402/ejpt.v7.31858.

[8]L. A. Zoellner, P. P. Roy-Byrne, M. Mavissakalian, and N. C. Feeny, "Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD," American Journal of Psychiatry, vol. 176, no. 4, pp. 287–296, Apr. 2019, doi: https://doi.org/10.1176/appi.ajp.2018.17090995.

[9]B. Graham, N. M. Garcia, H. E. Bergman, N. C. Feeny, and L. A. Zoellner, "Prolonged Exposure and Sertraline Treatments for Posttraumatic Stress Disorder Also Improve Multiple Indicators of Social Functioning," *Journal of Traumatic Stress*, vol. 33, no. 4, pp. 488–499, Jul. 2020, doi: https://doi.org/10.1002/jts.22570.

[10] F. Schneier and J. Goldmark, "Social Anxiety Disorder," Anxiety Disorders and Gender, pp. 49–67, 2015, doi: https://doi.org/10.1007/978-3-319-13060-6_3.

[11]M. Bernik, F. Corregiari, M. G. Savoia, T. P. de Barros Neto, C. Pinheiro, and F. L. Neto, "Concomitant treatment with sertraline and social skills training improves social skills acquisition in social anxiety disorder: A double-blind, randomized controlled trial," *PLOS ONE*, vol. 13, no. 10, p. e0205809, Oct. 2018, doi: https://doi.org/10.1371/journal.pone.0205809.

[12] A. Pelissolo, S. Abou Kassm, and L. Delhay, "Therapeutic strategies for social anxiety disorder: where are we now?," *Expert Review of Neurotherapeutics*, vol. 19, no. 12, pp. 1179–1189, Sep. 2019, doi: https://doi.org/10.1080/14737175.2019.1666713.

[13]D. J. Stein et al., "Obsessive–compulsive disorder," Nature Reviews Disease Primers, vol. 5, no. 1, p. 52, Aug. 2019, doi: https://doi.org/10.1038/s41572-019-0102-3.
[14]M. R. Faisal, H. Algristian, and N. Azizah AS, "Sertraline on Obsessive Compulsive Disorders in Indonesia (A Case Study)," International Islamic Medical Journal, vol. 4, no. 1, pp. 5–11, Feb. 2023, doi: https://doi.org/10.33086/iimj.v4i1.3602.

[15]L. M. Koran, E. Hackett, A. Rubin, R. Wolkow, and D. Robinson, "Efficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder," *American Journal of Psychiatry*, vol. 159, no. 1, pp. 88–95, Jan. 2002, doi: https://doi.org/10.1176/appi.ajp.159.1.88.

[16]G. J. Quallich, "Development of the commercial process for Zoloft®/sertraline," *Chirality*, vol. 17, no. S1, pp. S120–S126, 2005, doi: https://doi.org/10.1002/chir.20113.

[17] J. Y. Tan and G. M. Levin, "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy, vol. 19, no. 6, pp. 675–689, Jun. 1999, doi: https://doi.org/10.1592/phco.19.9.675.31538.

[18] P. Chitano, A. G. Stewart, T. M. Murphy, and A. J. Halayko, Trends reviews journals: Cell Press, http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(02)02101-6

[19] Mayo Clinic, "Selective Serotonin Reuptake Inhibitors (SSRIs)," Mayo Clinic, Sep. 17, 2019. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/ssris/art-20044825

[20] M. Isaac, "Where are we going with SSRIs?," European Neuropsychopharmacology, vol. 9, pp. S101–S106, Jul. 1999, doi: https://doi.org/10.1016/s0924-977x(99)00028-0.